Technology
Health
Biotechnology

Vical

$1.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (1.93%) Today
+$0.02 (1.93%) Today

Why Robinhood?

You can buy or sell Vical and other stocks, options, ETFs, and crypto commission-free!

About

Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Read More Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.

Employees
30
Headquarters
San Diego, California
Founded
1987
Market Cap
25.26M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
182.05K
High Today
$1.18
Low Today
$1.13
Open Price
$1.16
Volume
36.22K
52 Week High
$1.82
52 Week Low
$0.85

Collections

Technology
Health
Biotechnology
Research And Development
Biopharmaceutical
Pharmaceutical
US
North America

News

Seeking AlphaMar 7

Vical Is A Net Net In Liquidation Trading At Half Its Cash

On that date, book value per share was $2.24 and cash per share was $2.31 well above the current share price is $1.06. The company had cash and marketable securities of $50.5 million on December 31, 2018 and few liabilities. Going forward, R&D should be close to zero and administrative costs will be cut to less than $1.5 million per quarter. Net nets are hard to find. A net net is where the stock trades below working capital minus long-term liabilities. Usually they have all kinds of warts and are bleedi...

279
MarketBeatMar 4

NASDAQ:VICL - Stock Price, News, & Analysis for Vical

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

15
Guru FocusMar 1

Vical Inc (VICL) Files 10-K for the Fiscal Year Ended on December 31, 2018

Vical Inc (NASDAQ:VICL) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Vical Inc is engaged in research and development of biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

75

Earnings

-$0.30
-$0.22
-$0.15
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.